Renting the Molecule Factory: Pierre Fabre, XtalPi and Mid-Sized Pharma's AI Bet
Dr. Dereck Mush, MD, MBA
Laboratoires Pierre Fabre
Pharmaceutical research and development across oncology and other therapeutic areas.
What they do
Laboratoires Pierre Fabre and XtalPi announced a research and development collaboration on November 9, 2026. XtalPi will use AI and robotics to design novel small molecules against undisclosed targets; Pierre Fabre will contribute disease biology and development expertise and lead subsequent clinical and commercial development. The programs focus on oncology, potentially dermatology and rare diseases. Upfront payments, milestones and downstream economic participation are included, but amounts are undisclosed.
People in this update
- Francesco HofmannHead of Pharma Research and DevelopmentSource
The record
- Vertical
- Biotech & Drug Discovery
- Sub-segment
- AI drug discovery collaboration
- Product type
- Platform software
- Stage
- Headquarters
- Castres, France
- Region
- Europe
- Founded
- Not disclosed
- Total funding
- Undisclosed
Also in Biotech & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
Is AI Drug Discovery Actually Working? What the 2026 Clinical Trial Data Shows
Dr. Dereck Mush, MD, MBA